Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of… EP News Bureau Jan 24, 2022 The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per…
